RecruitingNCT06877416

Analysis of Exploring Optimized Sequential Treatment Strategies of Antibody-Drug Conjugates (ADCs) in HER2-Low-Expressing Breast Cancer

A Multi-center, Retrospective, Study on Exploring Optimized Sequential Treatment Strategies of Antibody-Drug Conjugates (ADCs) in HER2-Low-Expressing Breast Cancer

Sponsor

Sun Yat-sen University

Enrollment

700 participants

Start Date

Jan 1, 2020

Study Type

OBSERVATIONAL

Conditions

Breast Neoplasms HER2-low Breast Cancer Antibody-drug Conjugates

Summary

This study retrospectively analyzes the clinical data of HER2-low breast cancer (IHC 1+/2+ and FISH-negative) patients treated with sequential antibody-drug conjugates (ADCs). Key variables include patient demographics, tumor characteristics, ADC regimens (e.g., trastuzumab deruxtecan, sacituzumab govitecan), treatment sequencing, survival outcomes, and safety profiles. Genomic data (e.g., HER2 expression dynamics, TROP2 levels) are integrated to explore resistance mechanisms and prognostic biomarkers.mechanisms. This study aims to investigate the efficacy of different ADC sequential regimens in HER2-low breast cancer patients.

Eligibility

Plain Language Summary

Simplified for easier understanding

This study is reviewing real-world treatment data to understand how patients with HER2-low breast cancer fared when they received two or more different antibody-drug conjugates (ADCs — a type of targeted therapy that delivers chemotherapy directly to cancer cells) one after the other. **You may be eligible if...** - You have been diagnosed with HER2-low breast cancer (IHC 1+ or IHC 2+ with negative FISH test) - You received two or more different ADC therapies sequentially - Your medical records contain complete data on your treatment and follow-up **You may NOT be eligible if...** - You had another type of cancer at the same time as your breast cancer diagnosis - You have a history of any other malignant tumor - Your medical records are incomplete Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.